JP2015071589A - Disinfectant - Google Patents
Disinfectant Download PDFInfo
- Publication number
- JP2015071589A JP2015071589A JP2014164872A JP2014164872A JP2015071589A JP 2015071589 A JP2015071589 A JP 2015071589A JP 2014164872 A JP2014164872 A JP 2014164872A JP 2014164872 A JP2014164872 A JP 2014164872A JP 2015071589 A JP2015071589 A JP 2015071589A
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- less carbon
- disinfectant
- acid
- alkanolamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000645 desinfectant Substances 0.000 title claims abstract description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 63
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000002253 acid Substances 0.000 claims abstract description 29
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 18
- 241000700605 Viruses Species 0.000 claims abstract description 17
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 11
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000001630 malic acid Substances 0.000 claims abstract description 11
- 235000011090 malic acid Nutrition 0.000 claims abstract description 11
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 48
- 150000003973 alkyl amines Chemical class 0.000 claims description 34
- 150000001412 amines Chemical class 0.000 claims description 27
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 8
- 150000001340 alkali metals Chemical class 0.000 claims description 8
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 3
- 230000000249 desinfective effect Effects 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 abstract description 29
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 abstract description 5
- 235000009518 sodium iodide Nutrition 0.000 abstract description 5
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 abstract description 4
- 229940043276 diisopropanolamine Drugs 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 4
- 150000003751 zinc Chemical class 0.000 abstract description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 abstract description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 abstract description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 abstract description 3
- 229910001385 heavy metal Inorganic materials 0.000 abstract description 3
- 241000701161 unidentified adenovirus Species 0.000 abstract description 3
- 241000709661 Enterovirus Species 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 230000003253 viricidal effect Effects 0.000 description 31
- 244000309711 non-enveloped viruses Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- -1 conventionally Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000714201 Feline calicivirus Species 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 241001263478 Norovirus Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- UKXDHEBARGMWMO-ARJAWSKDSA-N (z)-4-(2-methylpropoxy)-4-oxobut-2-enoic acid Chemical compound CC(C)COC(=O)\C=C/C(O)=O UKXDHEBARGMWMO-ARJAWSKDSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GXJLQJFVFMCVHG-QXMHVHEDSA-N 2-methylpropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)C GXJLQJFVFMCVHG-QXMHVHEDSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100032373 Coiled-coil domain-containing protein 85B Human genes 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000868814 Homo sapiens Coiled-coil domain-containing protein 85B Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、消毒剤に関する。より具体的には、ノンエンベロープウイルスに対する殺ウイルス活性が高く且つ本来的に皮膚刺激性が少ない消毒剤に関する。 The present invention relates to a disinfectant. More specifically, the present invention relates to a disinfectant having high virucidal activity against non-enveloped viruses and inherently low skin irritation.
アルコールを主成分とする消毒剤は、生体消毒用として汎用され、最近では、手指消毒の第一選択となり、その適用範囲も拡大しつつある（例えば、非特許文献１）。 Alcohol-based disinfectants have been widely used for biological disinfection, and have recently become the first choice for hand disinfection, and their application range is expanding (for example, Non-Patent Document 1).
アルコール消毒剤は、広範囲の細菌及びウイルスに有効であるが、エンテロウイルスやアデノウイルスなどのノンエンベロープウイルスに対しては、短時間の作用では十分な効果が得られない（非特許文献１〜５、特許文献１及び２）。 Alcohol disinfectants are effective against a wide range of bacteria and viruses, but for non-enveloped viruses such as enteroviruses and adenoviruses, a sufficient effect cannot be obtained with a short action (Non-Patent Documents 1 to 5, Patent Documents 1 and 2).
このようなアルコール消毒剤に伴う問題に対しては、従来、アルカリ又は酸を添加して消毒剤のｐＨを強アルカリ性又は強酸性にすることが行われていた（非特許文献１、３〜６、特許文献１、４）。例えば、７６．９〜８１．４容量％のエタノールにリン酸を添加してｐＨを３以下（本発明者確認）とし、保湿剤としてグリセリン、ミリスチン酸イソプロピル及びアラントインを含む速乾性の手指消毒剤が販売されている（非特許文献１及び６）。
このような強酸性又は強アルカリ性の選択は、ノンエンベロープウイルスに対する殺ウイルス効果を高める意図でなされているものであるが、皮膚に対する刺激が強いことや、金属及び繊維に対する悪影響が指摘されている（非特許文献１、特許文献１）。
In order to solve the problems associated with such alcohol disinfectants, conventionally, alkali or acid has been added to make the disinfectant pH strongly alkaline or strongly acidic (Non-Patent Documents 1 to 6). Patent Documents 1 and 4). For example, a quick-drying hand disinfectant containing phosphoric acid in 76.9-81.4% by volume of ethanol to a pH of 3 or less (confirmed by the present inventor) and containing glycerin, isopropyl myristate and allantoin as moisturizers Are sold (Non-Patent Documents 1 and 6).
The selection of such strong acidity or strong alkalinity is made with the intention of enhancing the virucidal effect against non-enveloped viruses, but it has been pointed out that there is a strong irritation to the skin and an adverse effect on metals and fibers ( Non-patent document 1, Patent document 1).
これに対してｐＨを弱酸性から弱アルカリ性とする殺ウイルス用消毒剤も開発されている。例えば、亜鉛塩を低級アルコールに添加する消毒剤（特許文献３）、アルカリ金属の水酸化物、アンモニウム塩などのアルカリ性物質、及び塩化ベンザルコニウムなどのカチオン界面活性剤を低級アルコールに添加した消毒剤などが報告されている（特許文献２、非特許文献３）。
また、強酸又は強アルカリに伴う問題を取り扱うものではないが、乳酸及びクエン酸とともに亜鉛塩を低級アルコールに添加して即効性で持続的な消毒効果を狙った消毒剤も提案されている（特許文献１）。
On the other hand, a disinfectant for virucidal use whose pH is changed from weakly acidic to weakly alkaline has been developed. For example, a disinfectant in which a zinc salt is added to a lower alcohol (Patent Document 3), an alkaline substance such as an alkali metal hydroxide or an ammonium salt, and a cationic surfactant such as benzalkonium chloride are added to the lower alcohol. Agents and the like have been reported (Patent Document 2, Non-Patent Document 3).
In addition, although it does not deal with the problems associated with strong acids or strong alkalis, a disinfectant has also been proposed that aims for an immediate and sustained disinfection effect by adding a zinc salt together with lactic acid and citric acid to a lower alcohol (patent) Reference 1).
本発明は、このような従来のアルコール消毒剤に対し、弱酸から弱アルカリ性のｐＨを有し皮膚に対する刺激が少ないアルコール消毒剤としながらも、亜鉛塩などの重金属塩に寄らずにノンエンベロープウイルスに対しても短時間で十分な殺活性を発揮できる消毒剤を提供することを目的とする。 The present invention is an alcohol disinfectant having a weak acid to weak alkaline pH and less irritation to the skin compared to such a conventional alcohol disinfectant, but it is a non-enveloped virus without depending on heavy metal salts such as zinc salts. An object of the present invention is to provide a disinfectant capable of exhibiting sufficient killing activity in a short time.
本発明者らは、上記課題を解決すべく、様々な成分の組合せについて殺ウイルス活性を試験したところ、エタノール消毒剤にリン酸等の特定の酸と共にアミン、特に第一級又は第二級アミンを添加して消毒剤のｐＨを弱酸性から弱アルカリ性にしたところ、予想外にも、ノンエンベロープウイルスに対して短時間の作用で比較的高い殺活性を発揮することを見出した。また、このような酸とアミンを含むアルコール消毒剤に更に塩化ナトリウムなどの塩を添加すると、殺ウイルス活性が増強されることを見出した。 In order to solve the above-mentioned problems, the present inventors have tested the virucidal activity of various combinations of components. As a result, the ethanol disinfectant contains an amine, particularly a primary or secondary amine, together with a specific acid such as phosphoric acid. When the pH of the disinfectant was changed from weakly acidic to weakly alkaline, unexpectedly, it was found that it exhibits a relatively high killing activity with a short action against non-enveloped viruses. Further, it has been found that the addition of a salt such as sodium chloride to such an alcohol disinfectant containing an acid and an amine enhances the virucidal activity.
本発明はこのような知見に基づき、一の実施形態において、
（ａ）４０〜９０％（ｖ／ｖ）の低級アルコールと、
（ｂ）リン酸、リンゴ酸、又はこれら両方と、
（ｃ）炭素数５以下の第一級アルカノールアミン、炭素数５以下の第一級アルキルアミン、炭素数１０以下の第二級アルカノールアミン、炭素数１０以下の第二級アルキルアミン、炭素数１５以下の第三級アルカノールアミン及び炭素数１５以下の第三級アルキルアミンからなる群から選択される少なくとも１種のアミンと、
（ｄ）ハロゲンとアルカリ金属又はアルカリ土類金属との塩の少なくとも１種の塩と
を含み、ｐＨが４〜９である消毒剤を提供するものである。
この実施形態においては、より好ましくは、（ａ）４０〜９０％（ｖ／ｖ）の低級アルコールと、
（ｂ）０．１〜２％（ｗ／ｖ）のリン酸、リンゴ酸、又はこれら両方と、
（ｃ）０．１〜１０％（ｗ／ｖ）の炭素数５以下の第一級アルカノールアミン、炭素数５以下の第一級アルキルアミン、炭素数１０以下の第二級アルカノールアミン、炭素数１０以下の第二級アルキルアミン、炭素数１５以下の第三級アルカノールアミン及び炭素数１５以下の第三級アルキルアミンからなる群から選択される少なくとも１種のアミンと、
（ｄ）０．１〜２％（ｗ／ｖ）のハロゲンとアルカリ金属又はアルカリ土類金属との塩の少なくとも１種の塩と
を含み、ｐＨが４〜９である消毒剤が提供される。
Based on such knowledge, the present invention, in one embodiment,
(A) 40-90% (v / v) lower alcohol;
(B) phosphoric acid, malic acid, or both,
(C) primary alkanolamine having 5 or less carbon atoms, primary alkylamine having 5 or less carbon atoms, secondary alkanolamine having 10 or less carbon atoms, secondary alkylamine having 10 or less carbon atoms, carbon number 15 At least one amine selected from the group consisting of the following tertiary alkanolamines and tertiary alkylamines having 15 or less carbon atoms;
(D) providing a disinfectant having a pH of 4 to 9 and comprising at least one salt of a halogen and an alkali metal or alkaline earth metal salt.
In this embodiment, more preferably, (a) 40-90% (v / v) lower alcohol,
(B) 0.1-2% (w / v) phosphoric acid, malic acid, or both,
(C) 0.1 to 10% (w / v) primary alkanolamine having 5 or less carbon atoms, primary alkylamine having 5 or less carbon atoms, secondary alkanolamine having 10 or less carbon atoms, carbon number At least one amine selected from the group consisting of 10 or less secondary alkylamines, tertiary alkanolamines having 15 or less carbon atoms, and tertiary alkylamines having 15 or less carbon atoms;
(D) A disinfectant having a pH of 4 to 9 is provided, comprising 0.1 to 2% (w / v) halogen and at least one salt of an alkali metal or alkaline earth metal salt .
本発明はまた、他の実施の形態において、
（ａ）４０〜９０％（ｖ／ｖ）の低級アルコールと、
（ｂ）リン酸と、
（ｃ）炭素数５以下の第一級アルカノールアミン、炭素数５以下の第一級アルキルアミン、炭素数１０以下の第二級アルカノールアミン、炭素数１０以下の第二級アルキルアミン、炭素数１５以下の第三級アルカノールアミン及び炭素数１５以下の第三級アルキルアミンからなる群から選択される少なくとも１種のアミンと、
を含み、ｐＨが４〜９である消毒剤を提供する。
この実施の形態においても、より好ましくは、
（ａ）４０〜９０％（ｖ／ｖ）の低級アルコールと、
（ｂ）０．１〜２％（ｗ／ｖ）のリン酸と、
（ｃ）０．１〜１０％（ｗ／ｖ）の炭素数５以下の第一級アルカノールアミン、炭素数５以下の第一級アルキルアミン、炭素数１０以下の第二級アルカノールアミン、炭素数１０以下の第二級アルキルアミン、炭素数１５以下の第三級アルカノールアミン及び炭素数１５以下の第三級アルキルアミンからなる群から選択される少なくとも１種のアミンと、
を含み、ｐＨが４〜９である消毒剤が提供される。これらの実施形態の消毒剤においても、消毒剤は、好ましくは更に、（ｄ）ハロゲンとアルカリ金属又はアルカリ土類金属との塩の少なくとも１種を含み、このような塩は好ましくは０．１〜２％（ｗ／ｖ）含まれる。
The present invention also provides other embodiments,
(A) 40-90% (v / v) lower alcohol;
(B) phosphoric acid;
(C) primary alkanolamine having 5 or less carbon atoms, primary alkylamine having 5 or less carbon atoms, secondary alkanolamine having 10 or less carbon atoms, secondary alkylamine having 10 or less carbon atoms, carbon number 15 At least one amine selected from the group consisting of the following tertiary alkanolamines and tertiary alkylamines having 15 or less carbon atoms;
And a disinfectant having a pH of 4-9.
Also in this embodiment, more preferably,
(A) 40-90% (v / v) lower alcohol;
(B) 0.1-2% (w / v) phosphoric acid;
(C) 0.1 to 10% (w / v) primary alkanolamine having 5 or less carbon atoms, primary alkylamine having 5 or less carbon atoms, secondary alkanolamine having 10 or less carbon atoms, carbon number At least one amine selected from the group consisting of 10 or less secondary alkylamines, tertiary alkanolamines having 15 or less carbon atoms, and tertiary alkylamines having 15 or less carbon atoms;
And a disinfectant having a pH of 4-9. Also in the disinfectant of these embodiments, the disinfectant preferably further includes (d) at least one salt of a halogen and an alkali metal or an alkaline earth metal, and such a salt is preferably 0.1%. ˜2% (w / v) is included.
本発明はまた、更に他の実施の形態において、上記本発明の消毒剤を対象に接触させることを含む消毒方法を提供する。 In still another embodiment, the present invention provides a disinfection method including bringing the disinfectant of the present invention into contact with a subject.
本発明による消毒剤は、４〜９のｐＨを有する。従って、強酸性又は強アルカリ性とすることで殺ウイルス活性を増強する従来のアルコール消毒剤と異なり、このようなｐＨに起因する皮膚刺激等の問題を直接的に解決する手段を提供する。また、本発明による消毒剤は、このようなｐＨを有するにも拘らず、強酸性又は強アルカリ性の従来の消毒剤と同レベルでノンエンベロープウイルスに対する殺ウイルス効果、特に、即効性を発揮することができる。 The disinfectant according to the invention has a pH of 4-9. Therefore, unlike conventional alcohol disinfectants that enhance virucidal activity by making them strongly acidic or strongly alkaline, a means for directly solving problems such as skin irritation caused by such pH is provided. In addition, the disinfectant according to the present invention exhibits a virucidal effect on non-enveloped viruses at the same level as conventional strongly acidic or strongly alkaline disinfectants, in particular, although it has such a pH. Can do.
本発明の消毒剤は、低級アルコールをベースとし、特定の酸とアミンとを含み、弱酸から弱アルカリ性のｐＨを有するものである。以下、具体的に説明する。 The disinfectant of the present invention is based on a lower alcohol, contains a specific acid and an amine, and has a weak acid to weak alkaline pH. This will be specifically described below.
本発明の消毒剤で用いる低級アルコールは、典型的には炭素数５以下のアルコールであり、例えば、メタノール、エタノール、イソプロパノール、Ｎ−プロパノール、ブタノール又はこれらの混合物を挙げることができる。中でも毒性が低く、国内で汎用されている点でエタノール及びイソプロパノールが好ましい。イソプロパノールは、エンベロープを有するウイルスに対しては、エタノールよりも短い接触時間で有効であり、逆にエンベロープを持たないウイルスに対してはエタノールの方がより短時間で有効である。
消毒剤のアルコール含有量は、広範囲の細菌及びウイルスに対する殺効果の観点から、４０〜９０％（ｖ／ｖ）が好ましく、６０〜９０％（ｖ／ｖ）がより好ましく、７０〜９０％（ｖ／ｖ）が特に好ましい。なお、アルコール濃度の調整は、通常、精製水で行えばよい。
The lower alcohol used in the disinfectant of the present invention is typically an alcohol having 5 or less carbon atoms, and examples thereof include methanol, ethanol, isopropanol, N-propanol, butanol or a mixture thereof. Of these, ethanol and isopropanol are preferred because they are low in toxicity and widely used in Japan. Isopropanol is effective for a virus having an envelope with a shorter contact time than ethanol, and conversely, ethanol is effective for a virus having no envelope in a shorter time.
The alcohol content of the disinfectant is preferably 40 to 90% (v / v), more preferably 60 to 90% (v / v), and 70 to 90% (v / v) from the viewpoint of killing effects on a wide range of bacteria and viruses. v / v) is particularly preferred. In addition, what is necessary is just to perform adjustment of alcohol concentration with purified water normally.
本発明の消毒剤では、酸として、リン酸及びリンゴ酸の何れか１種又はこれらの組合せを含む。これらの酸は、後述するアミン及び任意に塩と組み合わせることで、弱酸性から弱アルカリ性の消毒剤としながらも、アルコールによるノンエンベロープウイルスに対する殺ウィルス活性を増強できる。中でも、リン酸はアルコールによる殺ウイルス活性の増強効果が大きいので、本発明の消毒剤では、酸として、リン酸又はこれとリンゴ酸の組合せを含むことが好ましく、リン酸単独を酸として含有するものが特に好ましい。
これら酸の含有量は、消毒剤のｐＨを弱酸から弱アルカリとするために後述するアミンの含有量に応じて調整されるが、殺ウイルス活性維持の点から消毒剤中０．１〜２％（ｗ／ｖ）含有することが好ましく、０．３〜１％（ｗ／ｖ）含有することがより好ましい。
In the disinfectant of the present invention, any one of phosphoric acid and malic acid or a combination thereof is included as the acid. These acids can enhance the virucidal activity against non-enveloped viruses caused by alcohols, in combination with amines and optionally salts described later, while being weakly acidic to weakly alkaline disinfectants. Among them, since phosphoric acid has a large effect of enhancing the virucidal activity by alcohol, the disinfectant of the present invention preferably contains phosphoric acid or a combination of this and malic acid as the acid, and contains phosphoric acid alone as the acid. Those are particularly preferred.
The content of these acids is adjusted according to the content of the amine described later in order to change the pH of the disinfectant from a weak acid to a weak alkali, but it is 0.1 to 2% in the disinfectant from the viewpoint of maintaining the virucidal activity. It is preferable to contain (w / v), and it is more preferable to contain 0.3 to 1% (w / v).
本発明の消毒剤では、塩基として、アミンを含み、第一級アルカノールアミン、第一級アルキルアミン、第二級アルカノールアミン、第二級アルキルアミン、第三級アルカノールアミン及び第三級アルキルアミンからなる群から選択される少なくとも１種を含むことが好ましい。第一級アルカノールアミンとしては、炭素数５以下のものが好ましく、例えば、モノエタノールアミン、モノｎ−プロパノールアミン、及びモノイソプロパノールアミン等を挙げることができる。第一級アルキルアミンとしても炭素数５以下のものが好ましく、例えば、エチルアミン、ｎ−プロピルアミン、及びイソプロピルアミン等を挙げることができる。また、第二級アルカノールアミンとしては、炭素数１０以下のものが好ましく、例えばジエタノールアミン、ジｎ−プロパノールアミン、及びジイソプロパノールアミン等を挙げることができ、第二級アルキルアミンとしても、炭素数１０以下のものが好ましく、例えばジエチルアミン等を挙げることができる。また、第三級アルカノールアミンとしては、炭素数１５以下のものが好ましく、例えばトリエタノールアミン、トリｎ−プロパノールアミン、及びトリイソプロパノールアミン等を挙げることができ、第三級アルキルアミンとしても、炭素数１５以下のものが好ましく、例えばトリエチルアミン等を挙げることができる。これらのアミンは、他の塩基とは異なり、上述したリン酸等を含む強酸性のアルコールに添加してｐＨを弱酸から弱アルカリとしても、アミン添加前の強酸性のアルコールと同レベルの殺ウイルス活性を発揮することができる。また、後述する塩との組合せで殺ウイルス活性を増強することができる。
上述したアミンの中でも、殺ウイルス活性の増強効果が大きな点で、第一級アルカノールアミン、第一級アルキルアミン、第二級アルカノールアミン、又は第二級アルキルアミンが好ましく、第一級アルカノールアミン又は第一級アルキルアミンがより好ましい。
The disinfectant of the present invention contains an amine as a base, and is composed of primary alkanolamine, primary alkylamine, secondary alkanolamine, secondary alkylamine, tertiary alkanolamine and tertiary alkylamine. It is preferable to include at least one selected from the group consisting of: As the primary alkanolamine, those having 5 or less carbon atoms are preferable, and examples thereof include monoethanolamine, mono-n-propanolamine, and monoisopropanolamine. The primary alkylamine is preferably one having 5 or less carbon atoms, and examples thereof include ethylamine, n-propylamine, and isopropylamine. Moreover, as a secondary alkanolamine, a C10 or less thing is preferable, for example, a diethanolamine, di n-propanolamine, a diisopropanolamine etc. can be mentioned, As a secondary alkylamine, it is C10. The following are preferred, and examples include diethylamine. Further, as the tertiary alkanolamine, those having 15 or less carbon atoms are preferable, and examples thereof include triethanolamine, tri-n-propanolamine, triisopropanolamine, and the like. Those having a number of 15 or less are preferred, and examples thereof include triethylamine. Unlike other bases, these amines are added to the above-mentioned strongly acidic alcohols containing phosphoric acid, etc., and even if the pH is changed from a weak acid to a weak alkali, the same level of virucidality as that of the strongly acidic alcohol before the amine addition. Can exhibit activity. Moreover, the virucidal activity can be enhanced by a combination with a salt described later.
Among the amines described above, primary alkanolamines, primary alkylamines, secondary alkanolamines, or secondary alkylamines are preferred in that the effect of enhancing the virucidal activity is large. Primary alkyl amines are more preferred.
これらアミンの含有量も、消毒剤のｐＨを弱酸〜弱アルカリとするために酸の含有量に応じて調整されるが、殺ウイルス活性維持の点から消毒剤中０．１〜１０％（ｗ／ｖ）含有することが好ましく、０．１５〜２％（ｗ／ｖ）含有することがより好ましく、０．３〜１％（ｗ／ｖ）含有することが更に好ましい。 The content of these amines is also adjusted according to the acid content in order to make the pH of the disinfectant weak acid to weak alkali, but from the point of maintaining the virucidal activity, 0.1 to 10% (w / V) is preferably contained, more preferably 0.15 to 2% (w / v), and still more preferably 0.3 to 1% (w / v).
本発明の消毒剤においては、更に、ハロゲンとアルカリ金属又はアルカリ土類金属との塩を含むことが好ましい。このような塩は、一般的には、殺ウイルス作用へ関与するものとは理解されていないが、驚くべきことに、これらの塩を上述の酸及びアミンと組み合わせると、殺ウイルス効果が更に増強される。
このような塩としては、例えば塩化ナトリウム、ヨウ化ナトリウム、塩化カルシウム、塩化カリウム、及び塩化マグネシウム等を挙げることができる。これらの塩の中でも、殺ウイルス活性の増強効果が大きな点で、塩化ナトリウム、ヨウ化ナトリウム又は塩化カリウムが好ましい。
これらの塩の含有量は、殺ウイルス活性の増強効果の点から、０．１％（ｗ／ｖ）以上が好ましく、アルコール溶液中の溶解性の点から、２％（ｗ／ｖ）以下が望ましい。また、７０〜９０％（ｖ／ｖ）の高アルコール濃度の消毒剤では、前述した点から、０．１〜０．３％（ｗ／ｖ）とすることが好ましい。なお、酸としてリン酸を含む消毒剤、好ましくは酸としてリン酸のみを含む消毒剤では、上述の塩なしで、十分な殺ノンエンベロープウイルス活性を発揮し得るが、殺ウイルス活性が更に増強される点で塩を含むことが好ましい。一方、酸としてリンゴ酸等のリン酸以外の酸のみを含む消毒剤では、上述の塩なしでは十分な殺ノンエンベロープウイルス活性を発揮し難い。従って、このような消毒剤では、特に塩を含有させることが好ましい。
The disinfectant of the present invention preferably further contains a salt of halogen and alkali metal or alkaline earth metal. Such salts are not generally understood to be involved in virucidal action, but surprisingly the combination of these salts with the acids and amines described above further enhances the virucidal effect. Is done.
Examples of such salts include sodium chloride, sodium iodide, calcium chloride, potassium chloride, and magnesium chloride. Among these salts, sodium chloride, sodium iodide, or potassium chloride is preferable in that the effect of enhancing the virucidal activity is large.
The content of these salts is preferably 0.1% (w / v) or more from the viewpoint of the effect of enhancing the virucidal activity, and 2% (w / v) or less from the viewpoint of solubility in the alcohol solution. desirable. Moreover, in the disinfectant of 70-90% (v / v) high alcohol concentration, it is preferable to set it as 0.1-0.3% (w / v) from the point mentioned above. Note that a disinfectant containing phosphoric acid as an acid, preferably a disinfectant containing only phosphoric acid as an acid, can exhibit sufficient non-envelope virus activity without the above-mentioned salt, but the virus-killing activity is further enhanced. In view of this, it is preferable to contain a salt. On the other hand, a disinfectant containing only acids other than phosphoric acid such as malic acid as an acid is unlikely to exhibit sufficient non-envelope virus activity without the above-described salt. Therefore, it is particularly preferable that such a disinfectant contains a salt.
本発明の消毒剤は、上述した酸とアミンとを組み合わせて消毒剤のｐＨを４〜９にすることを特徴とする。このようなｐＨの消毒剤では皮膚への刺激が少なく繊維や金属の影響も少ないが、ノンエンベロープウイルスに対する殺ウイルス活性が低下するといった問題が認識されていた。本発明の消毒剤は、このようなｐＨを有しながらも亜鉛イオンなどの重金属イオンに拠ることなくノンエンベロープウイルスに対する十分な殺ウイルス活性を有する。
ノンエンベロープウイルスに対してより高い殺ウイルス活性を付与する点では、ｐＨを４以上８未満とすることがより好ましく、４〜６とすることが更に好ましく、４〜５．５とすることが特に好ましい。本発明においては、上述の酸とアミンの含有量を調整することでこのようなｐＨを達成することが好ましい。具体的には、上述の酸とアミンとの重量比（酸：アミン）を、９：２〜１：５とすることが好ましく、６：２〜１：２とすることがより好ましく、１２：４〜３：４とすることが特に好ましい。
The disinfectant of the present invention is characterized by adjusting the pH of the disinfectant to 4 to 9 by combining the above-described acid and amine. Such pH disinfectants are less irritating to the skin and less affected by fibers and metals, but the problem of reduced virucidal activity against non-enveloped viruses has been recognized. The disinfectant of the present invention has sufficient virucidal activity against non-enveloped viruses without depending on heavy metal ions such as zinc ions while having such pH.
In terms of imparting higher virucidal activity to non-enveloped viruses, the pH is more preferably 4 or more and less than 8, more preferably 4 to 6, and particularly preferably 4 to 5.5. preferable. In the present invention, it is preferable to achieve such a pH by adjusting the contents of the acid and amine described above. Specifically, the above-mentioned weight ratio of acid to amine (acid: amine) is preferably 9: 2 to 1: 5, more preferably 6: 2 to 1: 2, and 12: 4 to 3: 4 is particularly preferable.
本発明の消毒剤では、添加物として、消炎剤、保湿剤、エモリエント剤、感触改善剤、増粘剤等を含んでもよい。 In the disinfectant of the present invention, flame retardants, moisturizers, emollients, feel improvers, thickeners and the like may be included as additives.
抗炎症剤としては、例えば、甘草エキス、グリチルレチン酸、グリチルリチン酸ジカリウム、グリチルレチン酸ステアリル、酢酸トコフェロール、アラントイン、及びアロエエキス等を挙げることができ、これら１種単独で又は２種以上含むことができる。 Examples of the anti-inflammatory agent include licorice extract, glycyrrhetinic acid, dipotassium glycyrrhizinate, stearyl glycyrrhetinate, tocopherol acetate, allantoin, and aloe extract. These can be used alone or in combination of two or more. .
保湿剤としては、例えば、アミノ酸、脂肪酸エステル、ピロリドンカルボン酸、ピロリドンカルボン酸ナトリウム、乳酸ナトリウム、ヒアルロン酸、ヒアルロン酸ナトリウム、Ｎ−ココイル−Ｌ−アルギニンエチルエステルＤＬ−ピロリドンカルボン酸塩、尿素、ソルビトール、トレハロース、１，３−ブチレングリコール、プロピレングリコール、及びグリセリン等を挙げることができ、これら１種単独で又は２種以上含むことができる。 Examples of humectants include amino acids, fatty acid esters, pyrrolidone carboxylic acid, sodium pyrrolidone carboxylate, sodium lactate, hyaluronic acid, sodium hyaluronate, N-cocoyl-L-arginine ethyl ester DL-pyrrolidone carboxylate, urea, sorbitol , Trehalose, 1,3-butylene glycol, propylene glycol, glycerin and the like, and these can be used alone or in combination of two or more.
エモリエント剤としては、例えば、ミリスチン酸イソプロピル、パルミチン酸イソプロピル、ステアリン酸イソプロピル、オレイン酸イソブチル、及びマレイン酸イソブチル等の脂肪酸エステルを挙げることができ、これら１種単独で又は２種以上含むことができる。 Examples of emollients include fatty acid esters such as isopropyl myristate, isopropyl palmitate, isopropyl stearate, isobutyl oleate, and isobutyl maleate, and these can be used alone or in combination of two or more. .
感触改善剤としては、例えば、ジメチルポリシロキサン、及び環状シリコーン等のシリコーン系化合物を挙げることができ、これら１種単独で又は２種以上含むことができる。 Examples of the feel improver include dimethylpolysiloxane and silicone compounds such as cyclic silicone, and these can be used alone or in combination of two or more.
増粘剤としては、例えばヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、疎水化ヒドロキシプロピルメチルセルロース、メチルセルロース及びカルボキシメチルセルロース等のセルロース誘導体、（メタ）アクリル酸系共重合体、ポリビニルアルコール、ポリビニルピロリドン、メチルビニルエーテル無水マレイン酸共重合体、ポリアクリルアミド、アルギン酸、アルギン酸ナトリウム、アルギン酸プロピレングリコールエステル、ゼラチン、アラビアゴム、トラガントゴム、ローカストビーンガム、グアガム、タマリンドガム、キサンタンガム、ジェランガム、及びカラギーナン等を挙げることができ、これら１種単独で又は２種以上含むことができる。 Examples of the thickener include cellulose derivatives such as hydroxyethylcellulose, hydroxypropylcellulose, hydrophobized hydroxypropylmethylcellulose, methylcellulose and carboxymethylcellulose, (meth) acrylic acid copolymers, polyvinyl alcohol, polyvinylpyrrolidone, methyl vinyl ether maleic anhydride Copolymers, polyacrylamide, alginic acid, sodium alginate, propylene glycol alginate, gelatin, gum arabic, tragacanth gum, locust bean gum, guar gum, tamarind gum, xanthan gum, gellan gum, carrageenan, etc. Or two or more.
本発明の消毒剤は、ノロウイルス、ポリオウイルス、アデノウイルス、及びロタウイルスなどのノンエンベロープウイルスに対して高い殺ウイルス効果を有することから、このようなウイルスに対する殺ウイルス用消毒剤として好適である。特に、ノロウイルスに対しては高い殺ウイルス効果を有する。また、インフルエンザウイルス等のエンベロープウイルスにも有効であり、広範囲の細菌にも有効である。 Since the disinfectant of the present invention has a high virucidal effect against non-enveloped viruses such as Norovirus, Poliovirus, Adenovirus, and Rotavirus, it is suitable as a disinfectant for virucidal activity against such viruses. In particular, it has a high virucidal effect on norovirus. It is also effective against envelope viruses such as influenza virus and is effective against a wide range of bacteria.
このため、本発明の消毒剤は、一般のアルコール消毒剤の用途に加え、ノンエンベロープウイルスの感染予防も必要となる状況で好適に用いることができる。また、本発明の消毒剤は、即効性に優れ且つ皮膚への刺激が少ないという特徴を有するため、手指消毒に好適であり、典型的には日常的手洗い、衛生的手洗い、手術時手洗いなどに使用できる。また、対象物に本発明の消毒剤を塗布等により接触させてウイルスを死滅又は増殖抑制するのも典型的な適用例の１つである。
使用方法については特に制限はなく、例えば、手指又は対象物に接触させ又は塗布することにより消毒を行うことができ、ラビング法、スワブ法など通常用いられる総ての方法を適用可能である。
For this reason, the disinfectant of the present invention can be suitably used in situations where it is necessary to prevent infection with non-enveloped viruses in addition to the use of general alcohol disinfectants. Further, the disinfectant of the present invention is characterized by excellent immediate effect and less irritation to the skin, and is therefore suitable for hand disinfection, typically for daily hand washing, sanitary hand washing, surgical hand washing, etc. Can be used. In addition, it is also a typical application example that the virus is killed or inhibited by bringing the disinfectant of the present invention into contact with an object by application or the like.
There is no particular limitation on the method of use, and for example, disinfection can be performed by contacting or applying to a finger or an object, and all commonly used methods such as a rubbing method and a swab method can be applied.
消毒剤の剤形についても特に制限はなく、液剤、ゲル剤、クリーム、フォームなど種々の形態とすることができ、各剤形に応じて適切な賦形剤を選択すればよい。 The dosage form of the disinfectant is not particularly limited, and various forms such as a liquid, a gel, a cream, and a foam can be used, and an appropriate excipient may be selected according to each dosage form.
以下、実施例を用いて本発明をより詳細に説明するが、本発明の技術的範囲は以下の実施例に限定されるものではない。 EXAMPLES Hereinafter, although this invention is demonstrated in detail using an Example, the technical scope of this invention is not limited to a following example.
１．消毒剤の調製
［実施例１］
９５％エタノール８３ｍｌに、リン酸０．５ｇ及びリンゴ酸０．０７ｇと、ジイソプロパノールアミン０．４２５ｇと、塩化ナトリウム０．２ｇとを添加し、更に精製水を加えて合計量を１００ｍｌとし、攪拌混合してｐＨ４．５の消毒剤を調製した。
［実施例２〜１７及び比較例１〜２７］
以下の表に示す組成としたこと以外は、実施例１と同様にして消毒剤を調製した。
1. Preparation of disinfectant [Example 1]
To 95 ml of 95% ethanol, add 0.5 g of phosphoric acid and 0.07 g of malic acid, 0.425 g of diisopropanolamine and 0.2 g of sodium chloride, and further add purified water to make a total volume of 100 ml. A disinfectant having a pH of 4.5 was prepared by mixing.
[Examples 2 to 17 and Comparative Examples 1 to 27]
A disinfectant was prepared in the same manner as in Example 1 except that the composition shown in the following table was used.
２．ノンエンベロープウイルスに対する殺ウイルス効果試験（１）
２−１．試験方法
ノンエンベロープウイルスに対する殺ウイルス効果をまず次の２つの簡易方法で評価した。
2. Test of virucidal effect against non-enveloped viruses (1)
2-1. Test Method The virucidal effect against non-enveloped viruses was first evaluated by the following two simple methods.
［ＦＣＶに対する殺ウイルス効果による試験］
ネコ腎由来株化細胞（ＣＲＦＫ ｃｅｌｌｓ） ＡＴＣＣ ＣＣＬ−９４にネコカリシウイルス（Ｆｅｌｉｎｅ Ｃａｌｉｃｉｖｉｒｕｓ： ＦＣＶ） ＡＴＣＣ ＶＲ−７８２を感染させた。ネコカリシウイルスはノロウイルスと同じカリシウイルス科に属しており、培養細胞系が確立していないノロウイルスの代替ウイルスとして使用されている。ウイルス液０．３ｍＬに２．７ｇ（２．７ｍＬ相当）の薬剤を混和し、次いで３０秒経過時に等量の培地で希釈することにより反応を停止した。次いでその試料を倍々希釈により希釈系列を作成し、得られた各希釈液をＣＲＦＫ細胞に感染させて培養した。
薬効は、ＣＲＦＫ細胞の細胞変性効果を指標とし５０％組織培養感染価（ＴＣＩＤ５０）の対数減少値を求めた。
[Test by virucidal effect on FCV]
Feline kidney-derived cell line (CRFK cells) ATCC CCL-94 was infected with feline calicivirus (FCV) ATCC VR-782. Feline calicivirus belongs to the same caliciviridae family as norovirus and is used as a substitute virus for norovirus for which no cultured cell line has been established. The reaction was stopped by mixing 2.7 g (equivalent to 2.7 mL) of the drug in 0.3 mL of the virus solution, and then diluting with an equal amount of medium when 30 seconds had elapsed. Next, a dilution series was prepared by doubling the sample, and each diluted solution obtained was infected with CRFK cells and cultured.
The drug efficacy was determined as a log reduction value of 50% tissue culture infectivity titer (TCID50) using the cytopathic effect of CRFK cells as an index.
［ＭＳ２ファージに対する殺ファージ効果による試験］
大腸菌（ＡＴＣＣ１５５９７）にＭＳ２ バクテリオファージ（ＡＴＣＣ１５９９７−Ｂ１）を感染させた。ＭＳ２ファージはノンエンベロープウイルスと薬剤抵抗性が類似しており、ウイルスに対する効果を類推する方法の１つとして使用されている。ファージ液１０μＬに９９０μＬの薬剤を混和し、次いで所定時間に一部をサンプリングし、ＬＰ中和液（３％レシチン、１０％ポリソルベート８０）で１００倍に希釈することにより、反応を停止した。その後、５０μＬの反応液を１００μＬの大腸菌培養液および２．５ｍＬのＡＴＣＣ ＃２７１軟寒天培地（１％Ｔｒｙｐｔｏｎｅ、０．１％Ｙｅａｓｔ Ｅｘｔｒａｃｔ、０．８％ＮａＣｌ、０．５％Ａｇａｒ）と混和し、ＡＴＣＣ ＃２７１寒天培地上に流し込んで培養した。
薬効は、作用前のファージ数を指標とし、ファージ数の対数減少値（ＬＲＶ）を求めた。
[Test by phage killing effect on MS2 phage]
E. coli (ATCC 15597) was infected with MS2 bacteriophage (ATCC 15997-B1). MS2 phage has drug resistance similar to that of non-enveloped viruses, and is used as one method for estimating the effect on viruses. The reaction was stopped by mixing 990 μL of the drug with 10 μL of the phage solution, then sampling a part at a predetermined time, and diluting 100 times with an LP neutralizing solution (3% lecithin, 10% polysorbate 80). Then, 50 μL of the reaction solution was mixed with 100 μL of E. coli culture solution and 2.5 mL of ATCC # 271 soft agar medium (1% Tryptone, 0.1% Yeast Extract, 0.8% NaCl, 0.5% Agar). The cells were poured onto ATCC # 271 agar medium and cultured.
The medicinal effect was determined by using the number of phages before the action as an index, and the logarithmic decrease value (LRV) of the number of phages.
２−２．試験結果
実施例１〜３及び比較例１〜７の消毒剤についてＦＣＶに対する殺ウイルス効果を試験した結果を表７に示し、実施例４〜１７、並びに比較例８〜２０の消毒剤についてＭＳ２ファージに対する殺ファージ効果を試験した結果を表８から１１に示し、比較例２１〜２７の消毒剤についてＦＣＶに対する殺ウイルス効果を試験した結果を表１２に示す。
す。
2-2. Test results The results of testing the virucidal effect on FCV for the disinfectants of Examples 1 to 3 and Comparative Examples 1 to 7 are shown in Table 7, and MS2 phage for the disinfectants of Examples 4 to 17 and Comparative Examples 8 to 20 Tables 8 to 11 show the results of testing the phage killing effect against No. 1, and Table 12 shows the results of testing the virus killing effect against FCV for the disinfectants of Comparative Examples 21 to 27.
The
ＥｔＯＨ：エタノール
ＩＰＡ：イソプロパノール
Ｐｈｏｓ：リン酸
ＬＡ：乳酸
ＣＡ：クエン酸
ＨＣｌ：塩酸
ＮａＣｌ：塩化ナトリウム
ＭｇＣｌ：塩化マグネシウム
Ｎａ２Ｓ２Ｏ３：チオ硫酸ナトリウム
ＮａＩ：ヨウ化ナトリウム
ＫＮＯ３：硝酸カリウム
ＡｃＮａ：酢酸ナトリウム
ＴＥＡ：トリエタノールアミン
ＤＩＰＡ：ジイソプロパノールアミン
ＤＥＡ：ジエタノールアミン
ＤＥＮ：ジエチルアミン
ＭＥＡ：モノエタノールアミン
Ａｓｃ：アスコルビン酸
ＭＡ：リンゴ酸
EtOH: ethanol IPA: isopropanol Phos: phosphoric acid LA: lactic acid CA: citric acid HCl: hydrochloric acid NaCl: sodium chloride MgCl: magnesium chloride Na 2 S 2 O 3 : sodium thiosulfate NaI: sodium iodide KNO 3 : potassium nitrate AcNa: acetic acid Sodium TEA: Triethanolamine DIPA: Diisopropanolamine DEA: Diethanolamine DEN: Diethylamine MEA: Monoethanolamine Asc: Ascorbic acid MA: Malic acid
３．ノンエンベロープウイルスに対する殺ウイルス効果試験（２）
マウス単球性白血病細胞株（ＲＡＷ ２６４．７ ｃｅｌｌｓ） ＡＴＣＣ Ｔ１Ｂ−７１にマウスノロウイルス（ＭＮＶ）を感染させた。ウイルス液０．３ｍＬに２．７ｇ（２．７ｍＬ相当）の実施例１の消毒剤を混和し、次いで３０秒経過時に等量の中和剤で希釈することにより反応を停止した。次いでその試料を倍々希釈により希釈系列を作成し、得られた各希釈液をＲＡＷ ２６４．７細胞に感染させて培養した。
薬効は、ＲＡＷ ２６４．７細胞の細胞変性効果を指標とし５０％組織培養感染価（ＴＣＩＤ５０）の対数減少値を求めた。試験結果を以下の表１３に示す。
Mouse monocytic leukemia cell line (RAW 264.7 cells) ATCC T1B-71 was infected with mouse norovirus (MNV). The reaction was stopped by mixing 2.7 g (equivalent to 2.7 mL) of the disinfectant of Example 1 in 0.3 mL of the virus solution and then diluting with an equal amount of neutralizing agent after 30 seconds. Next, a dilution series was prepared by doubling the sample, and each of the obtained dilutions was infected with RAW 264.7 cells and cultured.
The drug efficacy was determined as a log reduction value of 50% tissue culture infectivity titer (TCID50) using the cytopathic effect of RAW 264.7 cells as an index. The test results are shown in Table 13 below.
４．エンベロープウイルスに対する殺ウイルス効果の確認
イヌ腎臓尿細管上皮細胞（ＭＤＣＫ ｃｅｌｌｓ） ＡＴＣＣ ＣＣＬ−３４に鳥インフルエンザウイルス（Ｈ１Ｎ１、またはＨ５Ｎ１）を感染させた。ウイルス液０．３ｍＬに２．７ｇ（２．７ｍＬ相当）の実施例１の消毒剤を混和し、次いで３０秒経過時に等量の中和剤で希釈することにより反応を停止した。次いでその試料を倍々希釈により希釈系列を作成し、得られた各希釈液をＭＤＣＫ細胞に感染させて培養した。
薬効は、ＭＤＣＫ細胞の細胞変性効果を指標とし５０％組織培養感染価（ＴＣＩＤ５０）の対数減少値を求めた。
Ｈ１Ｎ１及びＨ５Ｎ１に対する殺ウイルス効果の試験結果を以下の表１４に示す。
実施例１の消毒剤は、消毒用エタノールと同様にエンベロープを持つインフルエンザウイルスにも高い殺ウイルス活性を有することが確認された。
4). Confirmation of virucidal effect on envelope virus Canine kidney tubular epithelial cells (MDCK cells) ATCC CCL-34 was infected with avian influenza virus (H1N1 or H5N1). The reaction was stopped by mixing 2.7 g (equivalent to 2.7 mL) of the disinfectant of Example 1 in 0.3 mL of the virus solution and then diluting with an equal amount of neutralizing agent after 30 seconds. Subsequently, a dilution series was prepared by doubling the sample, and each of the obtained dilutions was infected with MDCK cells and cultured.
The medicinal effect was determined by calculating the logarithmic decrease value of 50% tissue culture infectivity titer (TCID50) using the cytopathic effect of MDCK cells as an index.
The test results of the virucidal effect on H1N1 and H5N1 are shown in Table 14 below.
It was confirmed that the disinfectant of Example 1 has a high virucidal activity against influenza viruses having an envelope similar to disinfecting ethanol.
Claims (14)
（ｂ）リン酸、リンゴ酸、又はこれら両方と、
（ｃ）炭素数５以下の第一級アルカノールアミン、炭素数５以下の第一級アルキルアミン、炭素数１０以下の第二級アルカノールアミン、炭素数１０以下の第二級アルキルアミン、炭素数１５以下の第三級アルカノールアミン及び炭素数１５以下の第三級アルキルアミンからなる群から選択される少なくとも１種のアミンと、
（ｄ）ハロゲンとアルカリ金属又はアルカリ土類金属との塩の少なくとも１種と
を含み、ｐＨが４〜９である消毒剤。 (A) 40-90% (v / v) lower alcohol;
(B) phosphoric acid, malic acid, or both,
(C) primary alkanolamine having 5 or less carbon atoms, primary alkylamine having 5 or less carbon atoms, secondary alkanolamine having 10 or less carbon atoms, secondary alkylamine having 10 or less carbon atoms, carbon number 15 At least one amine selected from the group consisting of the following tertiary alkanolamines and tertiary alkylamines having 15 or less carbon atoms;
(D) A disinfectant comprising at least one salt of a halogen and an alkali metal or alkaline earth metal and having a pH of 4 to 9.
（ｂ）０．１〜２％（ｗ／ｖ）のリン酸、リンゴ酸、又はこれら両方と、
（ｃ）０．１〜１０％（ｗ／ｖ）の炭素数５以下の第一級アルカノールアミン、炭素数５以下の第一級アルキルアミン、炭素数１０以下の第二級アルカノールアミン、炭素数１０以下の第二級アルキルアミン、炭素数１５以下の第三級アルカノールアミン及び炭素数１５以下の第三級アルキルアミンからなる群から選択される少なくとも１種のアミンと、
（ｄ）０．１〜２％（ｗ／ｖ）のハロゲンとアルカリ金属又はアルカリ土類金属との塩の少なくとも１種と
を含み、ｐＨが４〜９である消毒剤。 (A) 40-90% (v / v) lower alcohol;
(B) 0.1-2% (w / v) phosphoric acid, malic acid, or both,
(C) 0.1 to 10% (w / v) primary alkanolamine having 5 or less carbon atoms, primary alkylamine having 5 or less carbon atoms, secondary alkanolamine having 10 or less carbon atoms, carbon number At least one amine selected from the group consisting of 10 or less secondary alkylamines, tertiary alkanolamines having 15 or less carbon atoms, and tertiary alkylamines having 15 or less carbon atoms;
(D) A disinfectant comprising 0.1 to 2% (w / v) halogen and at least one salt of an alkali metal or alkaline earth metal and having a pH of 4 to 9.
（ｂ）リン酸と、
（ｃ）炭素数５以下の第一級アルカノールアミン、炭素数５以下の第一級アルキルアミン、炭素数１０以下の第二級アルカノールアミン、炭素数１０以下の第二級アルキルアミン、炭素数１５以下の第三級アルカノールアミン及び炭素数１５以下の第三級アルキルアミンからなる群から選択される少なくとも１種のアミンと、
を含み、ｐＨが４〜９である消毒剤。 (A) 40-90% (v / v) lower alcohol;
(B) phosphoric acid;
(C) primary alkanolamine having 5 or less carbon atoms, primary alkylamine having 5 or less carbon atoms, secondary alkanolamine having 10 or less carbon atoms, secondary alkylamine having 10 or less carbon atoms, carbon number 15 At least one amine selected from the group consisting of the following tertiary alkanolamines and tertiary alkylamines having 15 or less carbon atoms;
And a disinfectant having a pH of 4-9.
（ｂ）０．１〜２％（ｗ／ｖ）のリン酸と、
（ｃ）０．１〜１０％（ｗ／ｖ）の炭素数５以下の第一級アルカノールアミン、炭素数５以下の第一級アルキルアミン、炭素数１０以下の第二級アルカノールアミン、炭素数１０以下の第二級アルキルアミン、炭素数１５以下の第三級アルカノールアミン及び炭素数１５以下の第三級アルキルアミンからなる群から選択される少なくとも１種のアミンと、
を含み、ｐＨが４〜９である消毒剤。 (A) 40-90% (v / v) lower alcohol;
(B) 0.1-2% (w / v) phosphoric acid;
(C) 0.1 to 10% (w / v) primary alkanolamine having 5 or less carbon atoms, primary alkylamine having 5 or less carbon atoms, secondary alkanolamine having 10 or less carbon atoms, carbon number At least one amine selected from the group consisting of 10 or less secondary alkylamines, tertiary alkanolamines having 15 or less carbon atoms, and tertiary alkylamines having 15 or less carbon atoms;
And a disinfectant having a pH of 4-9.
A disinfecting method comprising bringing the disinfectant according to any one of claims 1 to 13 into contact with a surface of a subject.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014164872A JP6286321B2 (en) | 2013-09-09 | 2014-08-13 | disinfectant |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013186450 | 2013-09-09 | ||
| JP2013186450 | 2013-09-09 | ||
| JP2014164872A JP6286321B2 (en) | 2013-09-09 | 2014-08-13 | disinfectant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015071589A true JP2015071589A (en) | 2015-04-16 |
| JP6286321B2 JP6286321B2 (en) | 2018-02-28 |
Family
ID=53014256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014164872A Active JP6286321B2 (en) | 2013-09-09 | 2014-08-13 | disinfectant |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6286321B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5849169B1 (en) * | 2015-05-26 | 2016-01-27 | 株式会社ニイタカ | Alcohol preparation for aluminum, sterilization method and virus inactivation method |
| JP2017105723A (en) * | 2015-12-09 | 2017-06-15 | サラヤ株式会社 | Composition having calicivirus inactivation effect |
| JP6339725B1 (en) * | 2017-05-23 | 2018-06-06 | 株式会社ニイタカ | Norovirus inactivator and sanitary material |
| JP2018127401A (en) * | 2017-02-06 | 2018-08-16 | 大日本除蟲菊株式会社 | Virus inactivation composition |
| JP2018197222A (en) * | 2017-11-01 | 2018-12-13 | 株式会社ニイタカ | Norovirus deactivator and sanitary material |
| JP2019156810A (en) * | 2018-03-16 | 2019-09-19 | 株式会社ニイタカ | Virus inactivator, norovirus inactivator, and hygiene material |
| JP2020125258A (en) * | 2019-02-04 | 2020-08-20 | 富士フイルム株式会社 | Composition, spray, and wiper |
| WO2022225049A1 (en) * | 2021-04-23 | 2022-10-27 | ミヨシ油脂株式会社 | Antibacterial agent, antibacterial composition using same and antiviral composition |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11209202A (en) * | 1998-01-21 | 1999-08-03 | Arbos:Kk | Tacky antimicrobial agent composition for toilet seat |
| JP2008143878A (en) * | 2006-12-13 | 2008-06-26 | Kawamoto Sangyo Kk | Disinfectant composition for digiti manus |
| JP2008523066A (en) * | 2004-12-09 | 2008-07-03 | ザ ダイアル コーポレイション | Composition having high antiviral and antibacterial effects |
| JP2008255101A (en) * | 2007-03-09 | 2008-10-23 | Maruishi Pharmaceutical Co Ltd | Disinfectant |
| JP2009161518A (en) * | 2007-12-13 | 2009-07-23 | Neos Co Ltd | Water-soluble antibacterial composition |
| JP2009173641A (en) * | 2007-12-27 | 2009-08-06 | Johnson Diversey Co Ltd | Bactericidal disinfectant composition, bactericidal disinfectant material comprising the same, and bactericidal disinfection method using the same composition or the same material |
| WO2010047108A1 (en) * | 2008-10-24 | 2010-04-29 | メルシャン株式会社 | Calicivirus inactivation method |
| JP2014019659A (en) * | 2012-07-13 | 2014-02-03 | Niitaka:Kk | Disinfection liquid and disinfection method |
| JP2016210807A (en) * | 2016-09-09 | 2016-12-15 | 株式会社ニイタカ | Disinfection solution and disinfection method |
-
2014
- 2014-08-13 JP JP2014164872A patent/JP6286321B2/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11209202A (en) * | 1998-01-21 | 1999-08-03 | Arbos:Kk | Tacky antimicrobial agent composition for toilet seat |
| JP2008523066A (en) * | 2004-12-09 | 2008-07-03 | ザ ダイアル コーポレイション | Composition having high antiviral and antibacterial effects |
| JP2008143878A (en) * | 2006-12-13 | 2008-06-26 | Kawamoto Sangyo Kk | Disinfectant composition for digiti manus |
| JP2008255101A (en) * | 2007-03-09 | 2008-10-23 | Maruishi Pharmaceutical Co Ltd | Disinfectant |
| JP2009161518A (en) * | 2007-12-13 | 2009-07-23 | Neos Co Ltd | Water-soluble antibacterial composition |
| JP2009173641A (en) * | 2007-12-27 | 2009-08-06 | Johnson Diversey Co Ltd | Bactericidal disinfectant composition, bactericidal disinfectant material comprising the same, and bactericidal disinfection method using the same composition or the same material |
| WO2010047108A1 (en) * | 2008-10-24 | 2010-04-29 | メルシャン株式会社 | Calicivirus inactivation method |
| JP2014019659A (en) * | 2012-07-13 | 2014-02-03 | Niitaka:Kk | Disinfection liquid and disinfection method |
| JP2016210807A (en) * | 2016-09-09 | 2016-12-15 | 株式会社ニイタカ | Disinfection solution and disinfection method |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5849169B1 (en) * | 2015-05-26 | 2016-01-27 | 株式会社ニイタカ | Alcohol preparation for aluminum, sterilization method and virus inactivation method |
| JP2016216430A (en) * | 2015-05-26 | 2016-12-22 | 株式会社ニイタカ | Alcohol preparation for aluminum, sterilization method |
| JP2017105723A (en) * | 2015-12-09 | 2017-06-15 | サラヤ株式会社 | Composition having calicivirus inactivation effect |
| JP2018127401A (en) * | 2017-02-06 | 2018-08-16 | 大日本除蟲菊株式会社 | Virus inactivation composition |
| JP2021120417A (en) * | 2017-02-06 | 2021-08-19 | 大日本除蟲菊株式会社 | Virus deactivation composition |
| JP6339725B1 (en) * | 2017-05-23 | 2018-06-06 | 株式会社ニイタカ | Norovirus inactivator and sanitary material |
| JP2018197204A (en) * | 2017-05-23 | 2018-12-13 | 株式会社ニイタカ | Norovirus deactivator and sanitary material |
| JP2018197222A (en) * | 2017-11-01 | 2018-12-13 | 株式会社ニイタカ | Norovirus deactivator and sanitary material |
| JP2019156810A (en) * | 2018-03-16 | 2019-09-19 | 株式会社ニイタカ | Virus inactivator, norovirus inactivator, and hygiene material |
| JP2020125258A (en) * | 2019-02-04 | 2020-08-20 | 富士フイルム株式会社 | Composition, spray, and wiper |
| JP7173888B2 (en) | 2019-02-04 | 2022-11-16 | 富士フイルム株式会社 | composition, spray, wiper |
| WO2022225049A1 (en) * | 2021-04-23 | 2022-10-27 | ミヨシ油脂株式会社 | Antibacterial agent, antibacterial composition using same and antiviral composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6286321B2 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6286321B2 (en) | disinfectant | |
| RU2436304C2 (en) | Disinfectant | |
| JP2017509634A (en) | Hand sanitizer with improved aesthetics and skin conditioning to encourage adherence to hand hygiene guidelines | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN106234439A (en) | A kind of superbacteria antibiosis and sterilization agent and its production and use | |
| JP2014019659A (en) | Disinfection liquid and disinfection method | |
| CN103766399A (en) | Iodine-containing disinfectant and preparation method thereof | |
| JP6783516B2 (en) | Composition having calicivirus inactivating effect | |
| CN104940191B (en) | A kind of fat-soluble nutgall catechin gallic acid palmitate disinfectant and preparation method | |
| CN104604849A (en) | Handwash-free disinfectant and preparation method thereof | |
| US9554994B2 (en) | Composition in form of a gel for the virucidal disinfection of mammalian skin | |
| CN103843770A (en) | Bactericidal composition containing fluopyram and fludioxonil | |
| RU2013147613A (en) | LOCAL DISINFECTANT OF IODINE CONTAINING LOW CONTENT OF SURFACE-ACTIVE SUBSTANCE | |
| KR20200009520A (en) | Process for Compositions of Disinfectants for High Pathogenic Avian Influenza Virus Including nano- and ionic-Minerals | |
| CN104434994A (en) | Mucocutaneous disinfectant | |
| CN103666890A (en) | Traditional Chinese medicinal liquid soap | |
| KR102143273B1 (en) | Process for Compositions of Disinfectants for Low Pathogenic Avian Influenza Virus Including nano- and ionic-Minerals | |
| CN105853676A (en) | Gallocatechin palmitate and alcohol compound disinfectant and preparation method thereof | |
| CN105726523A (en) | Drug composition for treating animal acariasises and preparation method and application thereof | |
| CN111888374A (en) | Microbial killing composition and preparation method thereof | |
| JP4587673B2 (en) | Cleaning composition | |
| CN108434006A (en) | A kind of leakage of liquid and preparation method thereof of prevention hand-foot-and-mouth disease | |
| KR102110503B1 (en) | Process for Compositions of Disinfection for Low Pathogenic Avian Influenza Virus Including Extract of Pleurotus nebrodensis | |
| RU2261089C1 (en) | Disinfecting agent | |
| AU2019307996B2 (en) | Disinfectant composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170228 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170925 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180112 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180124 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6286321 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |